Tier 2 — strong

Quercetin, but Not Epicatechin, Decreases Plasma Concentrations of Methylglyoxal in Adults in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial with Pure Flavonoids

Mathias D G Van den Eynde, Johanna M Geleijnse, Jean L J M Scheijen, Nordin M J Hanssen, James I Dower, Lydia A Afman, Coen D A Stehouwer, Peter C H Hollman, Casper G Schalkwijk
The Journal of nutrition 2018 148(12):1911-1916

Bibliography

PubMed
PMID 30398646
DOI
10.1093/jn/nxy236
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPost hoc analysis of a randomized double-blind crossover trial
ModelHuman intervention research
Sample37 adults with elevated screening systolic pressure
InterventionQuercetin-3-glucoside 160 mg/day, epicatechin 100 mg/day or placebo
Duration4-week treatment periods separated by 4-week washouts
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2018, this source examined cardiovascular and metabolic health. Design: Post hoc analysis of a randomized double-blind crossover trial. Sample/model: 37 adults with elevated screening systolic pressure. The exposure or intervention was Quercetin-3-glucoside 160 mg/day, epicatechin 100 mg/day or placebo. Follow-up or treatment period: 4-week treatment periods separated by 4-week washouts.

Quercetin reduced methylglyoxal by about 11%, without significant changes in the other measured dicarbonyls or advanced-glycation products.

Secondary analysis from the same trial as vascular reports. A methylglyoxal change is not proof of diabetes prevention or slower aging.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin reduced methylglyoxal by about 11%, without significant changes in the other measured dicarbonyls or advanced-glycation products.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin-3-glucoside 160 mg/day, epicatechin 100 mg/day or placebo; 4-week treatment periods separated by 4-week washouts.

What this study can and cannot tell us

  • Secondary analysis from the same trial as vascular reports. A methylglyoxal change is not proof of diabetes prevention or slower aging.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial
James I Dower et al. · The American journal of clinical nutrition · 2015
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015
Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology